How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?

Expert Opin Pharmacother. 2022 Jan;23(1):5-8. doi: 10.1080/14656566.2021.1961743. Epub 2021 Aug 17.

Authors

Daniele Roberto Giacobbe^{1

2}, Ilias Karaiskos³, Matteo Bassetti^{1

2}

Affiliations

¹ Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
² Clinica Malattie Infettive, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy.
³ 1st Department of Internal Medicine - Infectious Diseases, Hygeia General Hospital, Athens, Greece.

PMID: 34399631
DOI: 10.1080/14656566.2021.1961743

No abstract available

Keywords: Acinetobacter; CMS; Enterobacterales; Pseudomonas; colistin; polymyxin B.

Publication types

Editorial

MeSH terms

Anti-Bacterial Agents / therapeutic use
Colistin
Critical Illness*
Humans
Longevity
Microbial Sensitivity Tests
Polymyxin B
Polymyxins*

Substances

Anti-Bacterial Agents
Polymyxins
Polymyxin B
Colistin